LLY
NYSE · Pharmaceuticals
Eli Lilly and Co.
$1,102.08
+3.51 (+0.32%)
LLY News30 articles
Pfizer Stock Hovers Near Recent Lows After CFO Departure Sparks Growth Concerns
Pfizer shares remain near last week's selloff levels after CFO Dave Denton's planned departure raised concerns about growth and the company's obesity drug ambitions.
Pfizer Shares Slip as CFO Departure Rattles Investors; 2026 Outlook Intact
Pfizer shares fell 2.7% to $25.21 after CFO Dave Denton said he will leave in August, reigniting investor concerns over succession and obesity-drug competition.
Cathie Wood's ARK Invests $52M in Snowflake, Betting on AI Cloud Growth
ARK Investment Management bought $52 million in Snowflake shares following a 33% surge driven by raised guidance and a $6 billion AWS deal, signaling a bet on AI software revenue.
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.
Pfizer CFO Departure Casts Shadow on 2026 Growth Plans
Pfizer shares dropped 2.7% as CFO Dave Denton's departure raises fresh questions about the 2026 forecast and obesity drug pipeline.
Novo Nordisk Shares Rally as Healthcare Sector Lifts OMXC25
Novo Nordisk B shares rose 5% to 294.4 Danish crowns, leading the OMXC25 higher as healthcare stocks gained. The rally came amid a cyber incident and ongoing competition with Eli Lilly in oral obesity drugs.
Pfizer CFO Departure Raises Growth Strategy Questions, Stock Slips 3%
Pfizer shares slid 3.2% after announcing CFO Dave Denton's departure, intensifying investor scrutiny of the company's 2026 guidance and obesity drug strategy.
Pfizer Stock Rises on RBC Upgrade Despite German Drug-Pricing Threat
Pfizer shares rose 2.7% to $26.28 after RBC Capital upgraded the stock to Sector Perform, citing improved risk-reward. Meanwhile, a Reuters report flags German drug-pricing policy risks that could affect investments.
Hims & Hers Health Surges on Weight-Loss Drug Strategy Optimism
Hims & Hers Health (HIMS) shares rallied 6.6% to $28.98 on heavy volume, bucking a tech selloff, as investors refocus on the company's weight-loss drug scaling potential after a challenging quarter.
Pfizer Stock Dips Despite FDA Nod for Hemophilia Drug Hympavzi
Pfizer shares fell premarket despite FDA approval for hemophilia drug Hympavzi, as investors focus on slower obesity drug progress and pipeline challenges.
Novo Nordisk Shares Slide 4% Despite Wegovy Pill Prescriptions Surpassing 3 Million
Novo Nordisk shares dropped over 4% despite the Wegovy pill hitting 3 million U.S. prescriptions, as investors weighed profit margins against fierce competition from Eli Lilly and AstraZeneca.
Growth ETFs Rebound as Tech Rally Resumes, Concentration Risk in Focus
Growth ETFs rose sharply Monday as tech stocks rebounded, with QQQ up 2.2% and VUG gaining 1.2%. The rally highlights strong AI-driven inflows but also concentration risk.
Nurix Surges on Roche's $2.3B Cancer Drug Pact
Nurix shares soared premarket after Roche committed up to $2.3 billion for bexobrutideg, with $700 million upfront, validating the BTK degrader ahead of Phase 3 trials.
Eli Lilly Faces Market Test After Retatrutide Shows Broad Health Benefits
Eli Lilly's new obesity drug retatrutide showed 28.3% weight loss and improvements in sleep apnea and knee pain. The stock faces a key test Monday amid competing data from rivals.
Market Update: Warren Hits Trump Trades, Sage Dips 33%
Warren slams Trump's stock trades in Eli Lilly, Dell, and Micron. Sage drops 33% but analyst calls it a once-in-a-decade buy. Xiaomi falls 47.6% but near fair value.
Eli Lilly Hits Record Close on Retatrutide Data; Market Awaits Monday
Eli Lilly shares closed at a record $1,131.42 Friday after retatrutide data showed significant reductions in sleep apnea and knee osteoarthritis pain. Investors eye Monday's trade for market reaction.
Veru Stock Soars on Novo Nordisk Supply Deal for Obesity Trial
Veru shares jumped 88% to $4.23 after Novo Nordisk agreed to supply Wegovy for Veru's Phase 2b obesity trial. Analysts see it as a validation, but risks remain with trial endpoints and a 60-day exit clause.
CRISPR Therapeutics Surges 12% on Gene-Editing Sector Rally
CRISPR Therapeutics shares surged 12% in New York trading, buoyed by a sector-wide gene-editing rally and Eli Lilly's $1.9 billion deal with Ascidian Therapeutics.
Hims Completes $1.15B Eucalyptus Acquisition, Shares Dip Slightly
Hims & Hers shares fell 0.9% after completing the $1.15 billion Eucalyptus acquisition, gaining 850,000 customers and international reach, but facing execution risks and U.S. weight-loss drug plan shifts.
Abivax shares drop despite positive Phase 3 results for ulcerative colitis drug
Abivax shares plunged 33.7% after hours despite obefazimod achieving clinical remission in over 50% of patients in a Phase 3 trial. The company plans to submit an FDA application in late Q4 2026.
Pfizer's Cancer Pipeline Takes Center Stage After ASCO Data Dump
Pfizer enters Monday's trading with a wealth of new cancer drug data from ASCO and a $10.5B China partnership, positioning the stock for a potential re-rating.
Wall Street Hits Records; Dell's AI Revenue Surge Sparks After-Hours Rally
The S&P 500, Nasdaq, and Dow all closed at record highs Thursday. Dell surged 39% after hours on boosted AI-server revenue outlook, while PCE inflation hit 3.8% and GDP growth was revised lower.
S&P 500 and Nasdaq Rise as Dow Slips on Inflation Data and Ceasefire Hopes
The Dow slipped 0.08% Thursday, lagging the S&P 500 and Nasdaq, which rose on U.S.-Iran ceasefire hopes. Core PCE inflation hit 3.3%, and GDP growth was revised down to 1.6%.
Wall Street Mixed as Tech, Healthcare Lift S&P 500 and Nasdaq to Fresh Records
The S&P 500 and Nasdaq extended their record runs, driven by tech and healthcare stocks, as reports of a potential U.S.-Iran ceasefire lifted sentiment. The Dow edged lower, and inflation data remained elevated.
Lilly Expands Vaccine Portfolio with $3.83B Triple Acquisition
Eli Lilly acquires Curevo, LimmaTech, and Vaccine Company for up to $3.83B, gaining vaccine candidates for shingles, staph, and Epstein-Barr virus. Shares rose 5%.
Tech and AI Stocks Drive S&P 500 and Nasdaq Higher Amid Oil Price Surge
The S&P 500 and Nasdaq gained Tuesday, led by Micron crossing $1 trillion in market cap, as AI chip demand countered a rise in Brent crude above $100 and a drop in consumer confidence.
InMed Stock Retreats After 135% Merger Rally; Deal Dilution Weighs
InMed Pharmaceuticals shares fell 14.4% in pre-market trading Wednesday, giving back some of Tuesday's 135% surge on news of an all-stock merger with Mentari Therapeutics and a $290 million private placement.
Pfizer Faces Investor Scrutiny After Weekly Decline Amid Pipeline Concerns
Pfizer shares dropped 1.63% on Friday to $25.33, lagging the S&P 500. Despite a 5% revenue increase and reaffirmed 2026 guidance, investor caution persists over pipeline risks and competitive pressure from Eli Lilly.
MeiraGTx Stock Dips 5.5% After Weekly Slide; FDA Designation and Funding in Focus
MeiraGTx shares fell 5.5% Friday to $9.40, ending a 4.3% weekly drop, as the company reported a Q1 net loss of $46.3 million and advanced regulatory filings for key gene therapies.
Hims & Hers Stock Plunges on Q1 Loss, Weight-Loss Strategy Shift
Hims & Hers shares dropped 10% on a surprise Q1 net loss and revenue miss. The company raised its 2026 sales forecast but cut profit outlook amid a costly shift to branded weight-loss drugs.